Edward L Sutherland1, Agnieszka Choromanska2, Sayf Al-Katib2, Mary Coffey3. 1. Department of Diagnostic Radiology, William Beaumont Hospital, 3601 W 13 Mile Rd, Royal Oak, MI, 48073, USA. Edward.Sutherland@beaumont.org. 2. Department of Diagnostic Radiology, William Beaumont Hospital, 3601 W 13 Mile Rd, Royal Oak, MI, 48073, USA. 3. Beaumont Health Research Institute, 3601 W 13 Mile Rd, Royal Oak, MI, 48073, USA.
Abstract
PURPOSE: The purpose of this study was to evaluate the rate of nondiagnostic ultrasound-guided renal mass biopsies (RMBs) at our institution and to determine what patient, procedural, and focal renal mass (FRM) factors were associated with nondiagnostic ultrasound-guided RMBs. METHODS: Eighty-two ultrasound-guided renal mass biopsies performed between January 2014 and October 2016 were included in our study. Biopsy outcomes (diagnostic vs. nondiagnostic) and patient, procedural, and FRM characteristics were retrospectively reviewed and recorded. Univariate statistical analyses were performed to identify biopsy characteristics that were indicative of nondiagnostic biopsy. RESULTS: Ultrasound-guided RMBs were diagnostic in 70 out of 82 cases (85%) and non-diagnostic in 12 cases (15%). Among the diagnostic biopsies, 54 (77%) were malignant cases, 94% of which were renal cell carcinoma (RCC). Of the 12 nondiagnostic cases, the final diagnosis was RCC in 4 cases and angiomyolipoma in one case; seven of the nondiagnostic cases were lost to follow-up. A weak association (p = 0.04) was found between the number of needle passes and the biopsy outcome. None of the remaining collected RMB characteristics showed a significant correlation with a diagnostic or nondiagnostic RMB. Six patients (7%) experienced complications. CONCLUSION: Ultrasound-guided renal mass biopsy is a safe and effective method for the diagnosis of renal masses with a low rate of nondiagnostic outcomes. A nondiagnostic biopsy should not be treated as a surrogate for a diagnosis since a significant number of patients with nondiagnostic biopsies have subsequently been shown to have renal malignancies. Repeat biopsy should be considered in such cases.
PURPOSE: The purpose of this study was to evaluate the rate of nondiagnostic ultrasound-guided renal mass biopsies (RMBs) at our institution and to determine what patient, procedural, and focal renal mass (FRM) factors were associated with nondiagnostic ultrasound-guided RMBs. METHODS: Eighty-two ultrasound-guided renal mass biopsies performed between January 2014 and October 2016 were included in our study. Biopsy outcomes (diagnostic vs. nondiagnostic) and patient, procedural, and FRM characteristics were retrospectively reviewed and recorded. Univariate statistical analyses were performed to identify biopsy characteristics that were indicative of nondiagnostic biopsy. RESULTS: Ultrasound-guided RMBs were diagnostic in 70 out of 82 cases (85%) and non-diagnostic in 12 cases (15%). Among the diagnostic biopsies, 54 (77%) were malignant cases, 94% of which were renal cell carcinoma (RCC). Of the 12 nondiagnostic cases, the final diagnosis was RCC in 4 cases and angiomyolipoma in one case; seven of the nondiagnostic cases were lost to follow-up. A weak association (p = 0.04) was found between the number of needle passes and the biopsy outcome. None of the remaining collected RMB characteristics showed a significant correlation with a diagnostic or nondiagnostic RMB. Six patients (7%) experienced complications. CONCLUSION: Ultrasound-guided renal mass biopsy is a safe and effective method for the diagnosis of renal masses with a low rate of nondiagnostic outcomes. A nondiagnostic biopsy should not be treated as a surrogate for a diagnosis since a significant number of patients with nondiagnostic biopsies have subsequently been shown to have renal malignancies. Repeat biopsy should be considered in such cases.
Authors: P S Sidhu; K Brabrand; V Cantisani; J M Correas; X W Cui; M D'Onofrio; M Essig; S Freeman; O H Gilja; N Gritzmann; R F Havre; A Ignee; C Jenssen; A Kabaalioğlu; T Lorentzen; M Mohaupt; C Nicolau; C P Nolsøe; D Nürnberg; M Radzina; A Saftoiu; C Serra; Z Spârchez; I Sporea; C F Dietrich Journal: Ultraschall Med Date: 2015-12-15 Impact factor: 6.548
Authors: F Piscaglia; C Nolsøe; C F Dietrich; D O Cosgrove; O H Gilja; M Bachmann Nielsen; T Albrecht; L Barozzi; M Bertolotto; O Catalano; M Claudon; D A Clevert; J M Correas; M D'Onofrio; F M Drudi; J Eyding; M Giovannini; M Hocke; A Ignee; E M Jung; A S Klauser; N Lassau; E Leen; G Mathis; A Saftoiu; G Seidel; P S Sidhu; G ter Haar; D Timmerman; H P Weskott Journal: Ultraschall Med Date: 2011-08-26 Impact factor: 6.548
Authors: V Cantisani; M Bertolotto; H P Weskott; L Romanini; H Grazhdani; M Passamonti; F M Drudi; F Malpassini; A Isidori; F M Meloni; F Calliada; F D'Ambrosio Journal: Eur J Radiol Date: 2015-05-14 Impact factor: 3.528
Authors: Michael J Leveridge; Antonio Finelli; John R Kachura; Andrew Evans; Hannah Chung; Daniel A Shiff; Kimberly Fernandes; Michael A S Jewett Journal: Eur Urol Date: 2011-06-24 Impact factor: 20.096
Authors: Alessandro Volpe; Antonio Finelli; Inderbir S Gill; Michael A S Jewett; Guido Martignoni; Thomas J Polascik; Mesut Remzi; Robert G Uzzo Journal: Eur Urol Date: 2012-05-12 Impact factor: 20.096
Authors: Alessandro Volpe; Kamal Mattar; Antonio Finelli; John R Kachura; Andrew J Evans; William R Geddie; Michael A S Jewett Journal: J Urol Date: 2008-10-18 Impact factor: 7.450
Authors: Marta E Heilbrun; Ronald J Zagoria; A Julian Garvin; M Craig Hall; Kyle Krehbiel; Andrew Southwick; Peter E Clark Journal: AJR Am J Roentgenol Date: 2007-06 Impact factor: 3.959
Authors: Juan Camilo Álvarez Restrepo; David Andres Castañeda Millan; Carlos Andres Riveros Sabogal; Andres Felipe Puentes Bernal; Wilfredo Donoso Donoso Journal: J Kidney Cancer VHL Date: 2022-01-21